Indication
Platinum-resistant
1 clinical trial
1 product
2 drugs
Clinical trial
Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous TILs Followed by Low-Dose IL-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Re-stimulated TILsDrug
IL-2Drug
cyclophosphamide